Literature DB >> 10797293

Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China.

A L Stephen1, C H Thompson, M H Tattersall, Y E Cossart, B R Rose.   

Abstract

High rates of cervical cancer have been reported from parts of China and this may reflect a predominance of cervical infection with particularly aggressive human papillomavirus (HPV) variants. This PCR-based investigation of cervical tumours from Sichuan province in central China demonstrated an HPV positivity rate of 88%. HPV 16 was most common (21/34, 61%), followed by HPV 18 (3/34, 9%), while types 33, 45, 58 and 59 were each identified in one specimen. Sequencing of up to 1349 bases of the 21 HPV 16-positive isolates, encompassing the enhancer/promoter of the upstream regulatory region (URR) and the E6 and E7 genes, revealed distinct patterns of genomic stability and variability. An overall mutation rate of 5% was seen in the URR. One isolate had a large deletion of 436 bases in the enhancer; while varying combinations of 21 point mutations were identified in the remainder, impacting several YY1, NF1, TEF-1 and Oct-1 sites. More sequence variations were found in E6 compared to E7 (81% vs. 52% of isolates showing at least one mutation), some of which resulted in changes to the translated amino acids. Since the E6/E7 genes encode the oncogenic proteins essential for malignant transformation, and as their expression is controlled by the URR, it is possible that some of the identified mutations altered the oncogenicity of the virus: either directly by changing amino acid sequences of the E6 or E7 oncoproteins, or indirectly through alterations to transcription factor binding sites in the URR. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797293     DOI: 10.1002/(sici)1097-0215(20000601)86:5<695::aid-ijc15>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  HPV prevalence and genotyping in the cervix of Chinese women.

Authors:  Shao-Ming Wang; Jing Li; You-Lin Qiao
Journal:  Front Med China       Date:  2010-09-09

2.  Human papillomavirus type 16 variant analysis of E6, E7, and L1 [corrected] genes and long control region in [corrected] cervical carcinomas in patients in northeast China.

Authors:  Qinglong Shang; Yan Wang; Yong Fang; Lanlan Wei; Sijia Chen; Yuhui Sun; Baoxin Li; Fengmin Zhang; Hongxi Gu
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

3.  Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.

Authors:  Michael J Lace; Christina Isacson; James R Anson; Attila T Lörincz; Sharon P Wilczynski; Thomas H Haugen; Lubomír P Turek
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

4.  Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China.

Authors:  En-qi Wu; Guo-nan Zhang; Xiang-hui Yu; Yuan Ren; Ying Fan; Yong-ge Wu; Wei Kong; Xiao Zha
Journal:  BMC Cancer       Date:  2008-07-22       Impact factor: 4.430

5.  Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study.

Authors:  Stephanie Si Liu; Kelvin Yuen Kwong Chan; Rebecca Ching Yu Leung; Karen Kar Loen Chan; Kar Fai Tam; May Hiu Mei Luk; Sue Seen Tsing Lo; Daniel Yee Tak Fong; Annie Nga Yin Cheung; Zhong Qiu Lin; Hextan Yuen Sheung Ngan
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

6.  Sequence variation analysis of HPV-18 isolates in southwest China.

Authors:  Mengjie Shen; Xianping Ding; Tianjun Li; Gangyi Chen; Xiao Zhou
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

7.  Whole genome sequencing and evolutionary analysis of human papillomavirus type 16 in central China.

Authors:  Min Sun; Lei Gao; Ying Liu; Yiqiang Zhao; Xueqian Wang; Yaqi Pan; Tao Ning; Hong Cai; Haijun Yang; Weiwei Zhai; Yang Ke
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.